注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Dynavax Technologies Corp是一家商業階段的生物製藥公司,專注於疫苗的開發和商業化。該公司的產品包括HEPLISAV-B和CpG 1018。HEPLISAV-B用於預防18歲及以上成年人由已知的乙型肝炎病毒亞型引起的感染。HEPLISAV-B是一種用於成人的兩劑乙型肝炎疫苗。HEPLISAV-B是一種無菌注射溶液,裝在0.5毫升單劑量預裝注射器中。該公司還生產和銷售用於HEPLISAV-B的佐劑CpG 1018。該公司還通過研究合作和夥伴關係從事作為疫苗佐劑CpG 1018的開發。HEPLISAV-B結合了1018、toll樣受體(TLR9)激動劑佐劑和重組乙型肝炎表面抗原(rHBsAg)。其主要專注于冠狀病毒疾病(COVID-19)、鼠疫、百日咳(Tdap)、季節性流感、普遍流感和帶狀皰疹的佐劑疫苗。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Peggy V. Phillips | 67 | 2006 | Independent Director |
Daniel L. Kisner | 74 | 2010 | Independent Director |
Julie M. Eastland | 58 | 2020 | Independent Director |
Scott D. Myers | 57 | 2021 | Independent Chairman of the Board |
Robert L. Coffman | 76 | 2000 | Member of Scientific Advisory Board |
Francis R. Cano | 78 | 2009 | Independent Director |
Stanley A. Plotkin | 90 | 2005 | Member of Scientific Advisory Board |
Miriam Merad | - | 2018 | Member of Scientific Advisory Board |
Drew Mark Pardoll | - | 2018 | Member of Scientific Advisory Board |
E. John Wherry | - | 2018 | Member of Scientific Advisory Board |
Laura Q. M. Chow | - | 2018 | Member of Scientific Advisory Board |
Peter R. Paradiso | 72 | 2020 | Chairman of the Scientific Advisory Board & Independent Director |
Rino Rappuoli | 71 | 2023 | Member of Scientific Advisory Board |
Brent MacGregor | 59 | 2020 | Independent Director |
Elaine D. Sun | 51 | 2021 | Independent Director |
Kathryn M. Edwards | - | 2023 | Member of Scientific Advisory Board |
Ryan Spencer | 46 | 2019 | CEO, Interim CFO & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核